Bevacizumab-associated gastrointestinal perforation (Q47689626)

4 February 2018

title

Bevacizumab-associated gastrointestinal perforation (English)

1 reference

4 February 2018

1 reference

2

1 reference

4 February 2018

author name string

Ian Chau

series ordinal

1

1 reference

4 February 2018

publication date

1 June 2009

1 reference

4 February 2018

Lancet Oncology Commission

published in

1 reference

4 February 2018

volume

10

1 reference

4 February 2018

issue

6

1 reference

4 February 2018

page(s)

534-536

1 reference

4 February 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970142-1

7 January 2021

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970142-1

7 January 2021

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970142-1

7 January 2021

Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970142-1

7 January 2021

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970142-1

7 January 2021

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970142-1

7 January 2021

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970142-1

7 January 2021

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970142-1

7 January 2021

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970142-1

7 January 2021

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970142-1

7 January 2021

10.1016/S1470-2045(09)70142-1

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018